COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors.

Leonetti, Alessandro; Facchinetti, Francesco; Zielli, Teresa; Brianti, Elena; Tiseo, Marcello

Leonetti, Alessandro; Facchinetti, Francesco; Zielli, Teresa; Brianti, Elena; Tiseo, Marcello.

Leonetti A; Medical Oncology Unit, University Hospital of Parma, Parma, Italy; Department of Medicine and Surgery, University of Parma, Parma, Italy.
Facchinetti F; Université Paris-Saclay, Institut Gustave Roussy, Inserm, Biomarqueurs Prédictifs et Nouvelles Stratégies Thérapeutiques en Oncologie, 94800, Villejuif, France; Internal Medicine, Fidenza Hospital, Local Health Authority, Parma, Italy. Electronic address: Francesco.Facchinetti@gustaveroussy.fr.
Zielli T; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
Brianti E; Internal Medicine, Fidenza Hospital, Local Health Authority, Parma, Italy.
Tiseo M; Medical Oncology Unit, University Hospital of Parma, Parma, Italy; Department of Medicine and Surgery, University of Parma, Parma, Italy.

Eur J Cancer ; 132: 122-124, 2020 06.

Article in English | MEDLINE | ID: covidwho-148002

Subject(s)

Lung Neoplasms; Severe acute respiratory syndrome-related coronavirus; Betacoronavirus; COVID-19; China; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Severe acute respiratory syndrome-related coronavirus / Lung Neoplasms Limits: Humans Country/Region as subject: Asia Language: English Journal: Eur J Cancer Year: 2020 Document Type: Article Affiliation country: J.ejca.2020.04.004

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google